• Thomas White, Rafael Justiz, Michael Fishman, David Schultz, Aaron Calodney, Harold Cordner, Wilson Almonte, Yoann Millet, Kenneth Wu, Gennady Gekht, Andrew Will, Philip Kim, Richard Bundschu, Justin Sirianni, Amr El-Naggar, Mayank Gupta, Wesley Park, David L Cedeño, and Ricardo Vallejo.
• Procura Pain and Spine, Shenandoah, TX, USA.
• Neuromodulation. 2024 Dec 1; 27 (8): 144114481441-1448.

ObjectivesThis prospective, open-label, single-arm, multicenter study evaluated the use of differential target multiplexed (DTM) spinal cord stimulation (SCS) therapy for chronic upper limb pain (ULP).Materials And MethodsA total of 58 candidates for SCS who had chronic ULP were enrolled at 11 sites in the USA. The safety and effectiveness of DTM SCS for treating chronic intractable ULP were evaluated over 12 months. The primary end point was the percentage of responders (≥50% ULP relief versus baseline) to treatment at three months after device activation. This study also evaluated the extent of disability, patient satisfaction, and patient global impression of change with DTM SCS therapy.ResultsThe mean baseline pain score (10-cm visual analog scale [VAS-10]) for ULP was 7.2 cm, with a mean age of 56 years and mean ULP duration of ten years; 47 subjects were assessed at the primary end point. The percentage of ULP responders was 92% at three months, which was consistent at six (91%) and 12 months (86%). Significant ULP relief (81% reduction in VAS-10) was observed at the primary end point and sustained throughout the study duration. Significant improvements in disability in addition to high levels (>95%) of satisfaction and feelings of improvement were reported. Frequency of study-related anticipated adverse events was in line with expectations of SCS therapy.ConclusionIn this patient population with difficult-to-treat conditions with limited clinical evidence of the effectiveness of SCS, subjects reported significant reduction in chronic ULP in response to treatment with DTM SCS.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

22 keywords...

hide…